Home - PDF Document

Presentation Transcript

  1. Home ETCTN Trials by Disease/ Treatment Area: Sarcoma 10005: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma Alveolar soft part sarcoma 10015: A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma Unresectable or metastatic epithelioid hemangioendothelioma Potentially resectable: liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma (UPS)/ malignant fibrous histiosarcoma (MFH) 10056: A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Sarcoma 10330: A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma Chondrosarcoma Histology-confirmed EWSR1 translocation-positive clear cell sarcoma or conventional or dedifferentiated chondrosarcoma * 10398: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma ▼* 10387: Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection (Dose-Escalation: advanced solid tumors in patients with HIV infection; Expansion Kaposi’s sarcoma NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April17, 2020